Peter McWilliams, Ph.D.
Dr. McWilliams currently serves as Chief Executive Officer and is also a Managing Director with Sanderling Ventures. He has more than twenty years experience in biomedical research and management. He works actively with Sanderling portfolio companies often as a key member of the founding management team. Prior to joining Sanderling, Dr. McWilliams worked at Genentech, as a Product Manager in Oncology Commercial Development. Prior to that he was an Associate with Booz & Co (now PwC) in San Francisco and prior to that he worked for Oxford Molecular. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.
Giacomo Chiesi, M.B.A.
Giacomo Chiesi has over 10 years experience as a Board Member at the Chiesi Group, his family business. He currently serves both as Managing Partner at Chiesi Ventures and as Business Development Executive at Chiesi USA. In his tenure with the Chiesi Group he has directly structured and executed deals with $2B in value ranging from sell-side to buy-side M&A, in- and out-licensing, and spin-outs. In 2014, he founded Chiesi Ventures as a joint venture with Pappas Capital. Before going back to the Chiesi Group, Giacomo was a consultant with Bain & Co, where he led teams in a variety of assignments including due diligence, restructuring and strategy projects for consumer goods and IT companies in different countries. Previously he was with Accenture where he led large teams in outsourcing projects across Europe and US for clients in the transportation and retail business. Giacomo earned a M.Sc. degree Magna cum Laude in Telecommunications Engineering from the University of Parma, Italy, and an MBA from the University of Chicago Booth School of Business with concentrations in Entrepreneurship and Finance.